News & Updates

Conditional orders of low molecular weight heparin (LMWH) based on platelet values appears safe and effective in the treatment of venous thromboembolism (VTE) in patients with malignant haematology (MH) experiencing thrombocytopenia, a study has shown. In addition, worsening or new VTE has not been reported among study participants.

Use of rosuvastatin is associated with a significantly lower decline in left ventricular ejection fraction (LVEF) and lower serum levels of cardiotoxicity-associated biomarkers in newly diagnosed HER2-positive breast cancer patients treated with anthracycline-based chemotherapy followed by trastuzumab, according to the results of a prospective, randomized, controlled, parallel study.

Treatment with melphalan-prednisone-bortezomib (MPV) improves health-related quality of life (HRQoL) in both intermediate-fit and frail newly diagnosed multiple myeloma (NDMM) patients, according to the results of the prospective phase II HOVON123 trial.

Latest findings from the ongoing phase III NATALEE trial have shown that 3-year treatment with adjuvant ribociclib, in combination with a nonsteroidal aromatase inhibitor (NSAI), remained well tolerated in patients with HR+/HER2- early-stage breast cancer (EBC).

Long-term follow-up of the DESTINY-Breast03 trial has reported a median overall survival (OS) of 52.6 months with trastuzumab deruxtecan (T-DXd), representing the longest reported OS in previously treated HER2-positive metastatic breast cancer (mBC) to date.